NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.
As a result, the company can offer the microRNA-based test for the differentiation of the four main subtypes of lung cancer in all 50 states. New York had given the test, launched in July 2011, conditional approval in June.
"This represents an important validation of our technology as many jurisdictions around the world recognize the rigor of review in the state of New York," Rosetta President and CEO Kenneth Berlin said in a statement. "With the introduction of targeted lung cancer therapies, along with new targeted drugs entering the clinical arena, accurate classification of lung cancer is becoming increasingly important to better assess efficacy profiles and to enhance treatment strategies."